Annals of Diagnostic Pathology
Volume 12, Issue 2 , Pages 112-117 , April 2008

Lymphovascular space invasion does not predict vaginal relapses in stage I endometrioid adenocarcinoma of the endometrium

  • Laurephile Desrosiers, BS

      Affiliations

    • Department of Pathology, University of Massachusetts Medical Center, Worcester, MA 01605, USA
    • Equal contributors and co-first authors.
    • ,
  • Oluwole Fadare, MD

      Affiliations

    • Department of Pathology, Wilford Hall Medical Center, Lackland AFB, TX 78236, USA
    • Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    • Corresponding Author InformationCorresponding author. Department of Pathology, Wilford Hall Medical Center, Lackland AFB, TX 78236, USA.
    • Equal contributors and co-first authors.
    • ,
  • Zhefu F. Xiao

      Affiliations

    • Department of Pathology, University of Massachusetts Medical Center, Worcester, MA 01605, USA
    • ,
  • Karen Dresser

      Affiliations

    • Department of Pathology, University of Massachusetts Medical Center, Worcester, MA 01605, USA
    • ,
  • Sa A. Wang, MD

      Affiliations

    • Department of Pathology, University of Massachusetts Medical Center, Worcester, MA 01605, USA

References 

  1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8–29
  2. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, et al. Carcinoma of the corpus uteri. Int J Gynaecol Obstet. 2003;83(Suppl 1):79–118
  3. Clement PB, Young RH. Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol. 2002;9:145–184
  4. Prat J. Prognostic factors of endometrial carcinoma. Hum Pathol. 2004;35:649–662
  5. Viani GA, Patia BF, Pellizzon AC, De Meio MD, Novaes PE, et al. High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome. Radiat Oncol. 2006;1(1):24;[Electronic publication ahead of print]
  6. Ambros RA, Kurman RJ. Identification of patients with stage I uterine endometrioid adenocarcinoma at high risk of recurrence by DNA ploidy, myometrial invasion, and vascular invasion. Gynecol Oncol. 1992;45:235–239
  7. Ambros RA, Kurman RJ. Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus. Cancer. 1992;69:1424–1431
  8. Hanson MB, van Nagell JR, Powell DE, et al. The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer. Cancer. 1985;55:1753–1757
  9. Inoue Y, Obata K, Abe K, et al. The prognostic significance of vascular invasion by endometrial carcinoma. Cancer. 1996;78:1447–1451
  10. Sivridis E, Buckley C, Fox H. The prognostic significance of lymphatic vascular space invasion in endometrial adenocarcinoma. Br J Obstet Gynaecol. 1987;94:991–994
  11. Tsuruchi N, Kaku T, Kamura T, et al. The prognostic significance of lymphovascular space invasion in endometrial cancer when conventional hematoxylin and eosin staining is compared to immunohistochemical staining. Gynecol Oncol. 1995;57:307–312
  12. Bell J, Minnick A, Reid G, et al. Relationship of nonstaging pathologic risk factors to lymph node metastasis and recurrence in clinical stage 1 endometrial carcinoma. Gynecol Oncol. 1997;66:388–392
  13. Gal D, Recio F, Zamurovic D, et al. Lymphvascular space involvement: a prognostic indicator in endometrial adenocarcinoma. Gynecol Oncol. 1991;42:142–145
  14. Tornos C, Silva E, El-Naggar A, Burke TW. Aggressive stage I grade I endometrial carcinoma. Cancer. 1992;70:790–798
  15. Cohn DE, Horowitz NS, Mutch DG, et al. Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer?. Gynecol Oncol. 2002;87:243–246
  16. Zaino RJ, Kurman RJ, et al. Pathological models to predict outcome for women with endometrial adenocarcinoma: the importance of the distinction between surgical stage and clinical stage. Cancer. 1996;77:1115–1121
  17. Mariani A, Webb MJ, Keeney GL, Lesnick TG, Podratz KC. Surgical stage I endometrial cancer: predictors of distant failure and death. Gynecol Oncol. 2002;87:274–280
  18. Kadar N, Malfetano JH, Homesley HD. Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: implications for therapy. Obstet Gynecol. 1992;80:655–659
  19. Aalders JG, vd Syde R, Poppema S, Szabo BG, Janssens J. Prognostic factors and changing trends in the treatment of stage I endometrial cancer: a clinical and histopathological study of 182 patients. Int J Radiat Oncol Biol Phys. 1984;10:2083–2088
  20. Ayhan A, Tuncer ZS, Tuncer R, et al. Risk factors for recurrence in clinically early endometrial carcinoma: an analysis of 183 consecutive cases. Eur J Obstet Gynecol Reprod Biol. 1994;57:167–170
  21. MacLeod C, Fowler A, Duval P, D'Costa I, Dalrymple C, Firth I, et al. High-dose-rate brachytherapy alone post-hysterectomy for endometrial cancer. Int J Radiat Oncol Biol Phys. 1998;42:1033–1039
  22. Morrow CP, Bundy B, Kurman R, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a gynecologic oncology group study. Gynecol Oncol. 1991;40:55–65
  23. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–751
  24. Petereit DG, Tannehill SP, Grosen EA, Hartenbach EM, Schink JC. Outpatient vaginal cuff brachytherapy for endometrial cancer. Int J Gynecol Cancer. 1999;9:456–462
  25. Mariani A, Webb M, Keeney G, et al. Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol. 2002;84:437–442
  26. Lee KR, Vacek PM, Belinson JL. Traditional and nontraditional histopathologic predictors of recurrence in uterine endometrioid adenocarcinoma. Gynecol Oncol. 1994;54:10–18
  27. Horowitz NS, Peters WA, Smith MR, Drescher CW, Atwood M, Mate TP. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. Obstet Gynecol. 2002;99:235–240
  28. Mariani A, Dowdy SC, Keeney GL, Haddock MG, Lesnick TG, Podratz KC. Predictors of vaginal relapse in stage I endometrial cancer. Gynecol Oncol. 2005;97:820–827
  29. Alektiar KM, McKee A, Venkatraman E, McKee B, Zelefsky MJ, Mychalczak BR, et al. Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer. Int J Radiat Oncol Biol Phys. 2002;53:707–713
  30. Irwin C, Levin W, Fyles A, Pintilie M, Manchul L, Kirkbride P. The role of adjuvant radiotherapy in carcinoma of the endometrium—results in 550 patients with pathologic stage I disease. Gynecol Oncol. 1998;70:247–254
  31. Scholten AN, van Putten WL, Beerman H, Smit VT, Koper PC, Lybeert ML, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys. 2005;63:834–838
  32. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355:1404–1411
  33. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003;89:201–209
  34. Ackerman I, Malone S, Thomas G, Franssen E, Balogh J, Dembo A. Endometrial carcinoma-relative effectiveness of adjuvant irradiation vs therapy reserved for relapse. Gynecol Oncol. 1996;60:177–183
  35. Koh WJ, Tran AB, Douglas JG, Stelzer KJ. Radiation therapy inendometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2001;15:417–432
  36. Alektiar KM. When and how should adjuvant radiation be used in early endometrial cancer?. Semin Radiat Oncol. 2006;16(3):158–163
  37. Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC, van den Bergh AC, de Winter KA, Koper PC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol. 2004;22:1234–1241

☆ The opinions and/or assertions contained herein are solely those of the authors and should not be construed as official, or as representing the views of the US government or any of its subsidiaries.

PII: S1092-9134(07)00092-5

doi: 10.1016/j.anndiagpath.2007.05.009

Annals of Diagnostic Pathology
Volume 12, Issue 2 , Pages 112-117 , April 2008

Article Tools